Solventum Acquires Acera Surgical in $850 Million Wound-Care Deal

SolventumDealroom has a profile for this one. Try Dealroom → has announced an agreement to acquire Acera SurgicalDealroom has a profile for this one. Try Dealroom →, a privately held bioscience company focused on synthetic solutions for complex wound care. The deal includes an upfront payment of $725 million and up to $125 million. The acquisition is expected to close in the first half of 2026.

Acera Surgical, founded in 2013, develops electrospun, animal-free fibre matrices used to support soft-tissue repair and the treatment of difficult wounds. Its lead product, Restrata, is designed to provide a consistent alternative to biologic grafts by offering controlled structural properties and reliable manufacturing.

The company’s approach targets the expanding acute-care wound-management market, where synthetic materials are becoming increasingly attractive due to supply stability, lower variability and broader clinical applicability.

For Solventum, acquiring Acera adds a differentiated technology platform that complements its established wound-care and tissue-repair offerings, including negative-pressure wound therapy. The company plans to integrate Acera’s portfolio into its global commercial infrastructure, aiming to accelerate adoption in hospital and surgical settings.

Acera brings a product pipeline supported by clinical evidence, growing hospital uptake and a manufacturing base built around reproducible synthetic scaffolds. Solventum expects the combination to enhance its competitiveness in a segment where demand is rising due to ageing populations, diabetes prevalence and the increasing complexity of surgical care.

The announcement was accompanied by Solventum’s approval of a $1 billion share-buyback programme, underscoring the company’s confidence in its financial position as it pursues bolt-on acquisitions.

Sources:
Solventum
Solventum
Nasdaq
Medical Product Outsourcing

J.V.